Exclusive extracts from this 25-page-long report:
- Who is the player?
Bayer was created in 1863 and, over time, has evolved from a diversified chemicals group into a life science company with a focus on pharmaceuticals, health and agriculture. The final stage in the group's transformation into a life science company was achieved when Bayer ceded control of its MaterialScience division, Covestro [...].
- What are the player's strategies?
Following the massive portfolio adjustments that Bayer has undergone over the past few years (Covestro divestment, Monsanto acquisition, Merck and Dihon acquisitions) to become a life science company, the company has now shifted focus towards restructuring operations and maximising synergies. Further portfolio adjustments are envisaged. The company plans to exit the Animal Health business altogether and is currently exploring its options for a sale. […]
- What are the player's strengths and weaknesses?
Geographical diversification reduces exposure to any one region […]
Strong R&D capabilities and high R&D spending […]
Massive lawsuits pending following California court's finding that Roundup herbicide caused terminal cancer […]
Approaching patent cliff for two of its best-selling pharmaceutical products […]
- What is the player's financial position?
The financial indicators presented in the report include: Consolidated net revenues, Consolidated operating income and margin, Consolidated net profit and margin, R&D spending and ratio, Sales by segment, Sales performance by segment, Sales by region, Sales performance by region, Profitability ratios, Liquidity ratios, Solvency ratios and Free cash flow and capital expenditure.